Cellcolabs

The Cellcolabs Protocol outlines a validated manufacturing and quality system for pharmaceutical-grade mesenchymal stem cells.

All stem cells are manufactured at Cellcolabs’ GMP-certified facility in Stockholm, Sweden, approved by the Swedish Medical Products Agency.

Access high-quality GMP stem cells for approved medical or scientific use. For licensed professionals only.

Find out more about the science and research behind it all.

Overview of approved stem cell drugs and therapies, including regulatory pathways, clinical use, and how authorities evaluate safety and manufacturing.

Articles examining cost structures, reimbursement pathways, regulatory access models, and practical considerations in stem cell research and clinical use.

Educational articles about receiving stem cell treatment, including preparation, clinical procedures, safety considerations, and follow-up care.

Clinical standards, regulatory frameworks, manufacturing controls, and patient safety considerations in stem cell research and therapeutic development.

Cellcolabs and InnoHK CNRM partner to advance MSC therapy for knee osteoarthritis - Press | Cellcolabs

Cellcolabs announces the supply of adipose-derived mesenchymal stem cells for a Phase I clinical trial in Sjögren’s Syndrome at Rigshospitalet in Copenhagen.

Cellcolabs introduces its management and board of directors, who have expertise in stem cell research, life science, and responsible innovation.

Discover Cellcolabs, specializing in GMP mesenchymal stem cells (MSCs) for research, clinical trials, and scientific partnerships worldwide.

Cellcolabs offers research collaborations, cell sourcing, and general inquiries through its team.

Partner with Cellcolabs to access GMP-certified MSCs for research and biotech collaborations driving global advancements in regenerative medicine.

Cellcolabs produces GMP mesenchymal stem cells (MSCs) for clinical research and collaboration with clinics and scientists worldwide.

The local partner clinics and hubs that act as data processors on behalf of Cellcolabs AB for contact and health data transferred from Cellcolabs Clinical.

Terms of service information for cellcolabs.com visitors.

Cellcolabs secures $12 million in funding to expand operations. The Swedish stem cell startup serves high-profile clients, including longevity advocate Bryan Johnson and Silicon Valley figures. The investment supports further development of its stem cell-based therapies.

Oct 2025SiftedNews article

CellColabs announces a milestone in stem cell therapy, achieving scalable mass production capabilities. The startup’s advancements could lower costs and accelerate clinical applications for regenerative medicine. The company highlights progress toward commercializing stem cell treatments at an industrial scale.

Aug 2025The Next WebNews article

Bryan Johnson invests in stem cell injections to address knee joint pain, a growing issue among aging individuals. The procedure aims to reduce discomfort and improve mobility for those experiencing age-related joint deterioration. This reflects the expanding wellness industry’s focus on longevity solutions.

Aug 2024Business InsiderNews article

Cellcolabs secures $8.7 million in funding from angel investors to reduce the cost of producing specialized stem cells for disease treatment research. The Swedish biotech company manufactures stem cells applicable to multiple medical conditions, aiming to accelerate therapeutic development through affordability.

Mar 2024SiftedNews article